DILIsym is Quantitative Systems Toxicology (QST) software capable of predicting and explaining Drug-Induced Liver Injury (DILI).
Treating Systemic Lupus Erythematosus: How QSP Can Support Drug Development & Clinical Trial Design
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects more than five million people worldwide.
The Power of Using a Single PBPK Modeling and Simulation Platform
Physiologically-based pharmacokinetic (PBPK) modeling is now a standard tool used across the pharmaceutical industry to increase understanding of a drug’s behavior in the body and to help guide its development.
Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
Elevated liver fat content (LFC) is the primary pathophysiologic driver of metabolic dysfunction-associated steatohepatitis (MASH). In prior clinical trials, pemvidutide...
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
Acquisition doubles the Company’s TAM to $8 billion
Expected to be accretive to fiscal 2025 EPS
Conference call at 5:00PM ET to discuss transaction
Women in Science: Dr. Mitali Gaurav, Assistant Director, Pharmacometrics
The first algorithm ever developed for processing by machine was designed by Ada Lovelace, a pioneering mathematician in the 19th century.
Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes
Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy.
Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations
The use of in vitro-in vivo correlation (IVIVC) for extended release oral dosage forms is an important technique that can avoid potential clinical studies.
Construction of a physiologically based pharmacokinetic model of paclobutrazol and exposure estimation in the human body
Paclobutrazol (PBZ) is a plant growth regulator that can delay plant growth and improve plant resistance and yield. Although it has been widely used in the growth of medicinal plants, human beings may take it by taking traditional Chinese medicine.
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets
The United States Food and Drug Administration guidelines for the bioequivalence (BE) testing of the generic drug products suggests that there should be an equal proportion of male and female population in the BE study.
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Monolix Comparison Flyer
Your software should make it easier to conduct non-compartmental, bioequivalence and compartmental analysis and use that data to make the right decisions for your program.
Regulatory Strategies Flyer
Get to Market Faster with Robust Regulatory Strategies
Clinical Pharmacology & Pharmacometrics Software and Services Flyer
Supporting Dose Selection and Justification
Cheminformatics Software & Services Flyer
Understand Your Compound
PBPK Software and Services Flyer
Optimize Decision Making Throughout R&D with PBPK Predictions
Demystifying GPX™ Installation: Expert Insights and Practical Tips
Get ready to turbocharge your scientific team’s PBBM PBPK modeling technology with the latest version of GastroPlus®!
GPX™ The Next Level PBPK Platform
It’s here—the latest version of GastroPlus®, GPX. And this is your chance to see it in action.